Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain

Neutralizing antibodies (NAbs) are believed to be promising prophylactic and therapeutic treatment against the coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we reported two mouse monoclonal antibodies 7 Eb-4G and 1Ba–3H th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Guan-Chun, Chao, Tai-Ling, Lin, Shiau-Yu, Kao, Han-Chieh, Tsai, Ya-Min, Lu, De-Chao, Chiang, Yi-Wei, Chang, Sui-Yuan, Chang, Shih-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918075/
https://www.ncbi.nlm.nih.gov/pubmed/35296418
http://dx.doi.org/10.1016/j.antiviral.2022.105290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918075/
https://www.ncbi.nlm.nih.gov/pubmed/35296418
http://dx.doi.org/10.1016/j.antiviral.2022.105290

Ejemplares similares